

DAFTAR PUSTAKA

- ADA. (2015). Classification and diagnosis of diabetes. *Diabetes Care*, 38(January), S8–S16. <https://doi.org/10.2337/dc15-S005>
- ADA. (2017). Standards of Medical Care in Diabetes, The Journal of Clinical and Applied Research and Education. *American Diabetes Association*. doi: 10.2337/dc16-S003.
- Alefan, Q., AlImam, S., Mukattash, T., Mhaidat, N., Alabbadi, I., & Rascati, K. (2015). Pharmacoeconomics education in WHO Eastern Mediterranean region. *Currents in Pharmacy Teaching and Learning*, 7(6), 819–825. <https://doi.org/10.1016/j.cptl.2015.08.020>
- Ambianti, N., Andayani, T. M., & Sulistiawaty, E. (2019). Analisis Biaya Penyakit Diabetes Melitus Sebagai Pertimbangan Perencanaan Pembiayaan Kesehatan. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, 5(1), 73–83. <https://doi.org/10.22487/j24428744.2019.v5.i1.12071>
- Andayani, T.M. (2013). Farmakoekonomi: Prinsip dan Metodologi. *Bursa Ilmu. Yogyakarta*.
- Arini, H. D., Putu, Dian, M. K. (2019). Tinjauan Komparatif Studi Mengenai Efektivitas Biaya Antidiabetes Oral Pada Diabetes Melitus Tipe 2 Di Indonesia. *Acta Holistica Pharmaciana*. 2 (1) 6-17.
- Baroroh, F., Solikah, W. Y., & Urfiyya, Q. A. (2016). Analisis biaya terapi Diabetes Melitus tipe 2 Di Rumah Sakit Pku Muhammadiyah Bantul Yogyakarta. *Jurnal Farmasi Sains Dan Praktis*, 1(2), 11–22.
- Bukstein, D. A., & Luskin, A. T. (2017). Pharmacoeconomics of Biologic Therapy. *Immunology and Allergy Clinics of North America*, 37(2), 413–430. <https://doi.org/10.1016/j.iac.2017.01.011>
- de León-Castañeda, C. D., Altagracia-Martínez, M., Kravzov-Jinich, J., Cárdenas-Elizalde, M. del R., Moreno-Bonett, C., & Martínez-Núñez, J. M. (2012). Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. *ClinicoEconomics and Outcomes Research*, 4(1), 57–65. <https://doi.org/10.2147/CEOR.S27826>
- Diani, A., & Pulungan, A. B. (2016). Tata laksana Metformin Diabetes Mellitus Tipe 2 pada Anak Dibandingkan dengan obat Anti Diabetes Oral yang lain. *Sari Pediatri*, 11(6), 395. <https://doi.org/10.14238/sp11.6.2010.395-400>
- Dilokthornsakul, P., Thomas, D., Brown, L., & Chaiyakunapruk, N. (2019). Interpreting Pharmacoeconomic Findings. In *Clinical Pharmacy Education, Practice and Research*. Elsevier Inc. <https://doi.org/10.1016/b978-0-12-814276-9.00019-2>
- Dipiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G. et al (2011). *Pharmacotherapy: A Pathophysiologic Approach, 8th ed.*, Mc Graww Hill, United State of America.

- Ernawati. (2013). Penatalaksanaan Diabetes Mellitus Terpadu dengan Penerapan Teori Keperawatan Self Care Orem. Jakarta: *Mitra Wacana Media*.
- Fatimah N R. (2015). Diabetes Melitus Tipe 2. *Fakultas Kedokteran, Universitas Lampung*, 4(1302006088), 93–101.
- Fitri, E. (2015). Analisis Biaya Penyakit Diabetes Mellitus. *Jurnal Manajemen Dan Pelayanan Farmasi, Volume 5 N*.
- George, N., PV, A., & S., V. (2016). Glycemic control and cost-effectiveness attained by the drug utilization of oral antidiabetic agents in a tertiary care hospital in South India. *International Journal of Basic and Clinical Pharmacology*, 5(3), 684–691. <https://doi.org/10.18203/2319-2003.ijbcp20161501>
- IDF (International Diabetes Federation). (2017). Eighth edition 2017. In *IDF Diabetes Atlas, 8th edition*. [https://doi.org/http://dx.doi.org/10.1016/S0140-6736\(16\)31679-8](https://doi.org/http://dx.doi.org/10.1016/S0140-6736(16)31679-8).
- Khoiriyah, S. D. dan Keri L. (2018). Review Artikel: Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan Di Indonesia. *Farmaka*, 16, 1–15.
- Klarenbach, S., Cameron, C., Singh, S., Ehud. (2011). Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Cmaj*, 183(16)
- Kousoulakou, H., Hatzikou, M., Baroutsou, V., & Yfantopoulos, J. (2017). Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. *Cost Effectiveness and Resource Allocation*, 15(1), 1–7. <https://doi.org/10.1186/s12962-017-0082-7>
- Kurniawaty, Evi; Yanita, B. (2016). Faktor-Faktor yang Berhubungan dengan Kejadian Diabetes Melitus Tipe II. *Majority*, 5(2), 27–31. <http://juke.kedokteran.unila.ac.id/index.php/majority/article/view/1073>
- Megawati, F. et al. (2019). Gambaran Biaya Pasien Umum Rawat Inap Diabetes Mellitus Di Rumah Sakit Umum Ari Canti Periode Tahun 2017. *Jurnal Ilmiah Medicamento*, 5(1), 21–26.
- Menteri Kesehatan RI. (2014). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 56 Tahun 2014 Tentang Klasifikasi Dan Perizinan Rumah Sakit*. Jakarta : DEPKES RI.
- Menteri Kesehatan RI. (2020). *PMK Nomor 30/MENKES/PER/2020 tentang Klasifikasi dan Perizinan Rumah Sakit*. 3, 1–80.
- Ningrum, W. A., Muthoharoh, A., Q oyimah, M. (2019). Analisis Biaya Pengobatan Pasien Diabetes Mellitus Rawat Jalan Di RSUD Kraton Pekalongan. *Jurnal Pena*. 33(1) 15-21.
- Notoatmodjo, Soekidjo. (2010). *Prinsip-prinsip Dasar Ilmu Kesehatan Masyarakat*. Jakarta : Rineka Cipta.

- Perkumpulan Endokrinologi Indonesia. 2015. *Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia*. Jakarta. PB PERKENI.
- Pertiwi, P., Setiawan, D., & Perwitasari, D. A. (2018). Cost Effectiveness Analysis of Type-2 Antidiabetic Drugs in PKU Muhammadiyah Yogyakarta Hospital, Indonesia. *Advanced Science Letters*, 23(12), 12482–12485. <https://doi.org/10.1166/asl.2017.10797>
- Pribadi, F., & Permana, I. (2018). Analysis of the Cost-Effectiveness of Antidiabetic Drugs Among Self Paid Participant of the Indonesia National Security Service (NSS) with Type 2 Diabetes Mellitus. *International Journal of Medicine and Public Health*, 8(3), 108–111. <https://doi.org/10.5530/ijmedph.2018.3.23>
- Rahayu, A., & Rodiani. (2016). Efek Diabetes Melitus Gestasional terhadap Kelahiran Bayi Makrosomia. *Majority*, 5(4), 17–22.
- Rai, M., & Goyal, R. (2017). Pharmacoeconomics in Healthcare. In *Pharmaceutical Medicine and Translational Clinical Research*. Elsevier Inc. <https://doi.org/10.1016/B978-0-12-802103-3.00034-1>
- RISKESDAS. (2018). *HASIL UTAMA RISKESDAS 2018 Kesehatan*. 20–21. http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_2018/Hasil_Riskesdas_2018.pdf.
- Sari, R.M. (2014). Perbandingan Biaya Riil dengan Tarif Paket Ina-CBGs dan Analisis Faktor yang Mempengaruhi Biaya Riil pada Pasien Diabetes Melitus Rawat Inap Jamkesmas di RSUP Dr. Sardjito Yogyakarta. *SPREAD*. 4 (1): 61-70.
- Saroj Dhakal, Shrijana Shakya, & Shree Krishna Sharma. (2019). Cost-Effectiveness Analysis of Oral Hypoglycemics for Type-2 Diabetes Mellitus at a Tertiary Care Hospital, Nepal. *Journal of Pharmacy and Pharmacology*, 7(10), 546–556. <https://doi.org/10.17265/2328-2150/2019.10.004>
- Scaria, S., Raju, R., Joseph, S., Mohan, A., & Nair, A. A. (2015). Pharmacoeconomics: Principles, methods and Indian scenario. *International Journal of Pharmaceutical Sciences Review and Research*, 34(1), 37–46.
- Shahnaz, S., Khan, M. A., Alam, S., Ahmad, T., Ali, S. I., & Arain, M. I. (2020). *Research Article Cost-effectiveness Analysis of Oral Hypoglycemic Drugs for the Treatment of Type-II Diabetes Mellitus in a Tertiary Care Setup Karachi*. 61(08), 46–51.
- Singh, A., Dutta, S., Varma, A., Beg, M., Kumar, H., & Kaur, A. (2016). A drug utilization and pharmacoeconomic study of anti-diabetic drugs prescribed to type 2 diabetes mellitus patients visiting the medicine out-patient department of a tertiary care hospital of north India. *International Journal of Basic and Clinical Pharmacology*, 5(4), 1220–1227. <https://doi.org/10.18203/2319-2003.ijbcp20162219>
- Soewondo, P. (2014). Harapan Baru Penyandang Diabetes Mellitus pada Era Jaminan Kesehatan Nasional 2014. *EJournal Kedokteran Indonesia*, 2(1), 1–6. <https://doi.org/10.23886/ejki.2.3184>.

- Soewondo, P., Ferrario, A., & Tahapary, D. L. (2013). Challenges in diabetes management in Indonesia: A literature review. *Globalization and Health*, 9(1), 1–17. <https://doi.org/10.1186/1744-8603-9-63>.
- Soelistijo, S.A., Novinda, H., Rudijanto, A., Soewondo, P., Suastika, K., et al. (2015). *Konsensus Perkeni Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia 2015*. PB Perkeni, Jakarta.
- Sulistyorini, N., & Moediarso, B. (2012). *dengan Metode Distribusi Ganda*. 14(3), 65–72.
- Supartiningsih, S. (2017). Kualitas Pelayanan an Kepuasan Pasien Rumah Sakit: Kasus Pada Pasien Rawat Jalan. *Jurnal Medicoeticolegal Dan Manajemen Rumah Sakit* 10.18196/Jmmr.2016, 6(1), 9–15.
- Tamilselvan, T., Kumutha, T., Lekshmi, A., James, A. C., Reji, J. S., & Cheriyan, N. (2017). Pharmacoeconomical Evaluation of Oral Hypoglycemic Agents for Type-2 Diabetes Mellitus in a Multispeciality Hospital. *International Journal of Pharmaceutical Sciences and Research*, 8(5), 2243–2248. [https://doi.org/10.13040/IJPSR.0975-8232.8\(5\).2243-48](https://doi.org/10.13040/IJPSR.0975-8232.8(5).2243-48)
- Tjandrawinata, R. R. (2016). Peran Farmaekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan. *Working Paper of Dexa Medica Group*, 29(January 2016), 46–52.
- Tömöri, G., & Bács, Z. (2015). Application of Cost Analysis Methods in Pharmacoeconomic Decisions. *Procedia Economics and Finance*, 32(15), 416–422. [https://doi.org/10.1016/s2212-5671\(15\)01412-4](https://doi.org/10.1016/s2212-5671(15)01412-4)
- Toruan, Dwi, P. L., Darwin K., Rismadefi, W. (2018). Hubungan Motivasi Diri Dengan Kepatuhan Diet Pada Penderita Diabetes Melitus Tipe 2. *JOM FKp*. 5 (2).
- Utomo, M. R. S., Wungouw, H., & Marunduh, S. (2015). Kadar Hba1C Pada Pasien Diabetes Melitus Tipe 2 Di Puskesmas Bahu Kecamatan Malalayang Kota Manado. *Jurnal E-Biomedik*, 3(1), 3–11. <https://doi.org/10.35790/ebm.3.1.2015.6620>
- WHO Library. (2016). Global Report on Diabetes. *Isbn*, 978, 6–86. <http://www.who.int/about/licensing/>
- Wisudanti. (2016). Aplikasi Terapeutik Geranin Dari Ekstrak Kulit Rambutan (*Nephelium lappaceum*) Sebagai Anti Hiperglikemik Melalui Aktivitasnya Sebagai Antioksidan Pada Diabetes Melitus Tipe 2. *Nurseline Journal*, 1–19.
- Zhuo, X., Zhang, P., & Hoerger, T. J. (2013). Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. *American Journal of Preventive Medicine*, 45(3), 253–261.